Esperion Therapeutics (ESPR) Other Operating Expenses (2020 - 2026)

Esperion Therapeutics' Other Operating Expenses history runs 7 years deep, the most recent figure standing at $34.6 million for Q1 2026.

• Quarterly Other Operating Expenses rose 9.62% year-over-year to $34.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.4 million (down 190.36% YoY) and the FY2025 annual result came in at -$84.4 million, down 223.05% from the prior year.
• Other Operating Expenses was $34.6 million for Q1 2026 at Esperion Therapeutics, up from -$185.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $41.3 million in Q3 2025 and bottomed at -$185.8 million in Q4 2025.
• A 5-year average of $5.2 million and a median of $11.7 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses surged 409.78% — and 2025, when it sank 824.84%.
• Esperion Therapeutics' Other Operating Expenses stood at $4.2 million in 2022, then jumped by 175.29% to $11.5 million in 2023, then soared by 123.81% to $25.6 million in 2024, then sank by 824.84% to -$185.8 million in 2025, then soared by 118.61% to $34.6 million in 2026.
• Business Quant data shows ESPR's Other Operating Expenses at $34.6 million in Q1 2026, -$185.8 million in Q4 2025, and $41.3 million in Q3 2025.